To err is human, to persist is diabolical: Are we repeating the same cost and insurance coverage mistakes again with injectable PrEP?
Emerging data suggests high interest in injectable PrEP but low uptake, with some participants reporting challenges obtaining insurance coverage, alongside other clinic-level barriers. It is our hope that assessments of current and persisting barriers to cabotegravir can offer preliminary but critical insights for the rollout of lenacapavir.
Authors
- Christian Grov (ORCID: https://orcid.org/0000-0001-6871-3531)
- Viraj V. Patel (ORCID: https://orcid.org/0000-0002-5603-9823)
- Alexa B. D’Angelo (ORCID: https://orcid.org/0000-0001-5260-340X)
- Adam W. Carrico (ORCID: https://orcid.org/0000-0002-8146-5701)
Institutions
- The Graduate Center, CUNY (US)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1097/qai.0000000000003817
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00